Literature DB >> 12072645

Crystal-cell interaction in the pathogenesis of kidney stone disease.

Marino Asselman1, Carl Friedrich Verkoelen.   

Abstract

PURPOSE OF REVIEW: Renal stone formation depends not so much on the formation of crystals, but on their retention in the kidney. Evidence has emerged that crystal retention is caused predominantly by the adherence of crystals to the epithelial cells lining the renal tubules. Understanding the mechanisms involved in crystal retention could lead to new therapeutic approaches for interfering with the renal stone-forming process in patients. Cell-culture studies have been performed to obtain insights into the susceptibility of the cell surface to crystal attachment, and to uncover cell-surface crystal-binding molecules. This review aims to put the relevant publications of the last decade in perspective. RECENT
FINDINGS: Crystal-cell interaction has been investigated by using various renal tubular cell types in culture. Such studies have yielded several candidate crystal-binding molecules, including phosphatidylserine, sialic acid, collagen IV, osteopontin and, recently, hyaluronan.
SUMMARY: Here, the results obtained in crystal-binding studies are recapitulated, compared and evaluated. Arguments are provided in support of the view that many of the proposed crystal-binding molecules could be linked in the series of events resulting in crystal retention. Under pathological conditions, pericellular matrices rich in the polysaccharide hyaluronan are proposed as the key binding substance for crystals at the surface of renal tubular cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12072645     DOI: 10.1097/00042307-200207000-00002

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  8 in total

1.  The effect of intracrystalline and surface-bound osteopontin on the degradation and dissolution of calcium oxalate dihydrate crystals in MDCKII cells.

Authors:  Lauren A Thurgood; Esben S Sørensen; Rosemary L Ryall
Journal:  Urol Res       Date:  2011-09-20

2.  Calcium oxalate calculi-induced clusterin expression in kidney.

Authors:  Jin-Yi Li; Junjiang Liu; Junyi Jiang; Chris Pumill; Cordelia Elaiho; Yunxia Zhang; Shoubin Li; Tie Zhou
Journal:  Urolithiasis       Date:  2015-05-21       Impact factor: 3.436

3.  Stress-stones-stress-recurrent stones: a self-propagating cycle? Difficulties in solving this dichotomy.

Authors:  Montserrat Arzoz-Fabregas; Josep Roca-Antonio; Luis Ibarz-Servio; Dalielah Jappie-Mahomed; Allen Rodgers
Journal:  Urolithiasis       Date:  2017-03-21       Impact factor: 3.436

Review 4.  Phosphorylated proteins and control over apatite nucleation, crystal growth, and inhibition.

Authors:  Anne George; Arthur Veis
Journal:  Chem Rev       Date:  2008-10-03       Impact factor: 60.622

5.  Microbial Community Transplant Results in Increased and Long-Term Oxalate Degradation.

Authors:  Aaron W Miller; Kelly F Oakeson; Colin Dale; M Denise Dearing
Journal:  Microb Ecol       Date:  2016-06-16       Impact factor: 4.552

6.  Reinjury risk of nano-calcium oxalate monohydrate and calcium oxalate dihydrate crystals on injured renal epithelial cells: aggravation of crystal adhesion and aggregation.

Authors:  Qiong-Zhi Gan; Xin-Yuan Sun; Poonam Bhadja; Xiu-Qiong Yao; Jian-Ming Ouyang
Journal:  Int J Nanomedicine       Date:  2016-06-14

7.  Two independent modes of kidney stone suppression achieved by AIM/CD5L and KIM-1.

Authors:  Kyohei Matsuura; Natsumi Maehara; Aika Hirota; Ayaka Eguchi; Keisuke Yasuda; Kaori Taniguchi; Akemi Nishijima; Nobuyuki Matsuhashi; Yoshiyuki Shiga; Rumi Ishii; Yasuhiro Iguchi; Kazunari Tanabe; Satoko Arai; Toru Miyazaki
Journal:  Commun Biol       Date:  2022-08-03

8.  Immunohistochemical localization and mRNA quantification of osteopontin and Tamm-Horsfall protein in canine renal tissue after potassium oxalate injection.

Authors:  Walaa Mohamaden; Heng Wang; Huawei Guan; Xia Meng; Jianji Li
Journal:  BMC Vet Res       Date:  2014-03-17       Impact factor: 2.741

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.